Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-07-02

Clinical Trial Update: Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of AC-3933 in adults with mild to moderate Alzheimer's disease has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AC-3933

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2013-07-02